These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 10962448)
1. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Hombach A; Schneider C; Sent D; Koch D; Willemsen RA; Diehl V; Kruis W; Bolhuis RL; Pohl C; Abken H Int J Cancer; 2000 Oct; 88(1):115-20. PubMed ID: 10962448 [TBL] [Abstract][Full Text] [Related]
2. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755 [TBL] [Abstract][Full Text] [Related]
3. Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA. Nolan KF; Yun CO; Akamatsu Y; Murphy JC; Leung SO; Beecham EJ; Junghans RP Clin Cancer Res; 1999 Dec; 5(12):3928-41. PubMed ID: 10632322 [TBL] [Abstract][Full Text] [Related]
4. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. Hombach A; Wieczarkowiecz A; Marquardt T; Heuser C; Usai L; Pohl C; Seliger B; Abken H J Immunol; 2001 Dec; 167(11):6123-31. PubMed ID: 11714771 [TBL] [Abstract][Full Text] [Related]
5. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ; Darcy PK J Immunol; 2001 Jan; 166(1):182-7. PubMed ID: 11123291 [TBL] [Abstract][Full Text] [Related]
6. Targeting of T cells to CEA-expressing tumor cells by chimeric immune receptors with a highly specific single-chain anti-CEA activity. Arakawa F; Shibaguchi H; Xu Z; Kuroki M Anticancer Res; 2002; 22(6C):4285-9. PubMed ID: 12553071 [TBL] [Abstract][Full Text] [Related]
7. Construction and molecular characterization of human chimeric T-cell antigen receptors specific for carcinoembryonic antigen. Shirasu N; Shibaguci H; Kuroki M; Yamada H; Kuroki M Anticancer Res; 2010 Jul; 30(7):2731-8. PubMed ID: 20683006 [TBL] [Abstract][Full Text] [Related]
8. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation. Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958 [TBL] [Abstract][Full Text] [Related]
9. A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently. Wang XB; Zhao BF; Zhao Q; Piao JH; Liu J; Lin Q; Huang HL J Biochem; 2004 Apr; 135(4):555-65. PubMed ID: 15115782 [TBL] [Abstract][Full Text] [Related]
10. Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains. Roberts MR; Cooke KS; Tran AC; Smith KA; Lin WY; Wang M; Dull TJ; Farson D; Zsebo KM; Finer MH J Immunol; 1998 Jul; 161(1):375-84. PubMed ID: 9647246 [TBL] [Abstract][Full Text] [Related]
11. Carcinoembryonic antigen-immunoglobulin Fc fusion protein (CEA-Fc) for identification and activation of anti-CEA immunoglobulin-T-cell receptor-modified T cells, representative of a new class of Ig fusion proteins. Ma Q; DeMarte L; Wang Y; Stanners CP; Junghans RP Cancer Gene Ther; 2004 Apr; 11(4):297-306. PubMed ID: 15002034 [TBL] [Abstract][Full Text] [Related]
12. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Moritz D; Groner B Gene Ther; 1995 Oct; 2(8):539-46. PubMed ID: 8593604 [TBL] [Abstract][Full Text] [Related]
13. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo. Schirrmann T; Pecher G Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290 [TBL] [Abstract][Full Text] [Related]
14. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. Darcy PK; Haynes NM; Snook MB; Trapani JA; Cerruti L; Jane SM; Smyth MJ J Immunol; 2000 Apr; 164(7):3705-12. PubMed ID: 10725729 [TBL] [Abstract][Full Text] [Related]
15. [T lymphocytes with chimeric receptor induce carcinoembryonic antigen-positive specific gastric carcinoma cells apoptosis]. Xu HY; Xu L; Gao JH; Li KZ; Dou KF Zhonghua Yi Xue Za Zhi; 2007 Apr; 87(15):1053-7. PubMed ID: 17672971 [TBL] [Abstract][Full Text] [Related]
16. Specific targeting strategies of cancer gene therapy using a single-chain variable fragment (scFv) with a high affinity for CEA. Kuroki M; Arakawa F; Khare PD; Kuroki M; Liao S; Matsumoto H; Abe H; Imakiire T Anticancer Res; 2000; 20(6A):4067-71. PubMed ID: 11131674 [TBL] [Abstract][Full Text] [Related]
17. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins. Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154 [TBL] [Abstract][Full Text] [Related]
18. Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains. Hombach A; Sircar R; Heuser C; Tillmann T; Diehl V; Kruis W; Pohl C; Abken H Int J Mol Med; 1998 Jul; 2(1):99-103. PubMed ID: 9854151 [TBL] [Abstract][Full Text] [Related]
19. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Hombach A; Koch D; Sircar R; Heuser C; Diehl V; Kruis W; Pohl C; Abken H Gene Ther; 1999 Feb; 6(2):300-4. PubMed ID: 10435115 [TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. Altenschmidt U; Klundt E; Groner B J Immunol; 1997 Dec; 159(11):5509-15. PubMed ID: 9548491 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]